Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 2,737 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuroendocrine Tumours Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Tailored Intervention for Melanoma Patient's Families

NCT00816374
View directory record Official record
Conditions
Melanoma
Interventions
Reading materials and discussions, Questionnaires
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
21 Years and older
Enrollment
553 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
3
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 19, 2026, 10:43 PM EDT
Recruiting Not applicable Interventional

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

NCT03860883
View directory record Official record
Conditions
Cutaneous Melanoma, Stage II
Interventions
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Procedure
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
2,998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
128
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

NCT00667641
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, paclitaxel
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 10, 2011 · Synced Oct 19, 2026, 10:43 PM EDT
Not listed Phase 1 Interventional

Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors

NCT01381822
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumors, Pancreatic Neuroendocrine Tumors
Interventions
TH-302
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Goshen, Indiana • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 19, 2026, 10:43 PM EDT
Terminated Phase 1 Interventional Results available

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

NCT01400451
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab (BMS-734016), Vemurafenib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2015 · Synced Oct 19, 2026, 10:43 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NCT03375320
View directory record Official record
Conditions
Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
432
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 289 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 19, 2026, 10:43 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Harvesting Cells for Experimental Cancer Treatments

NCT00068003
View directory record Official record
Conditions
Melanoma, Gastrointestinal Cancer, Metastatic Cancer, Breast Cancer, Non-Small Cell Lung Cancer
Interventions
Anti-CD19 CAR PBL
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 10:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

NCT07749586
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
ARV-6723, Pembrolizumab, SOC
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
New York, New York • Huntersville, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 10:43 PM EDT
Not listed Phase 3 Interventional

Vaccine Therapy for Patients With Stage IV Melanoma

NCT00052156
View directory record Official record
Conditions
Malignant Melanoma
Interventions
CancerVax vaccine (CANVAXIN)
Biological
Lead sponsor
CancerVax Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
51
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

NCT00498979
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
recombinant interferon alfa-2b, cisplatin, sodium stibogluconate, dacarbazine, vinblastine
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 19, 2026, 10:43 PM EDT
Active, not recruiting Phase 1 Interventional

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

NCT05176470
View directory record Official record
Conditions
Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Stage IV Melanoma
Interventions
Cyclophosphamide, Fludarabine, Lifileucel, Pembrolizumab, Therapeutic Conventional Surgery
Drug · Biological · Procedure
Lead sponsor
Richard Wu
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

NCT00001683
View directory record Official record
Conditions
Lymphoma, Melanoma, Neoplasm Metastasis, Renal Cell Carcinoma
Interventions
COL-3
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

NCT03008369
View directory record Official record
Conditions
Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma
Interventions
Laboratory Biomarker Analysis, Lenvatinib, Quality-of-Life Assessment
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Not applicable Interventional

Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38

NCT00912574
View directory record Official record
Conditions
Melanoma
Interventions
GM-CSF-in-adjuvant, Montanide ISA-51, GM-CSF and Montanide ISA-51, Saline
Drug · Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

NCT03319459
View directory record Official record
Conditions
HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor, Advanced Solid Tumors, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreatic Cancer, Melanoma
Interventions
FATE-NK100, Cetuximab, Trastuzumab
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
San Diego, California • Minneapolis, Minnesota • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

NCT02514824
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
MLN0128
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

NCT00324155
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Placebo, Dacarbazine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
32
States / cities
Anaheim, California • La Verne, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Oct 19, 2026, 10:43 PM EDT
Terminated Phase 1 Interventional

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

NCT03809624
View directory record Official record
Conditions
Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
Interventions
INBRX-105 - PDL1x41BB antibody, Pembrolizumab
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
23
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00054535
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, recombinant fowlpox-tyrosinase vaccine, vaccinia-tyrosinase vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 19, 2026, 10:43 PM EDT
Terminated Phase 1 Interventional

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

NCT01212276
View directory record Official record
Conditions
Metastatic Melanoma, Malignant Metastatic Melanoma, Advanced Melanoma, Melanoma
Interventions
MORAb-028
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 19, 2026, 10:43 PM EDT
Recruiting No phase listed Observational

Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment

NCT01205815
View directory record Official record
Conditions
Melanoma
Interventions
Tissue and blood collection
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 19, 2026, 10:43 PM EDT
Completed No phase listed Observational

Molecular Epidemiology of Cutaneous Malignant Melanoma

NCT00341991
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
15,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

NCT01152788
View directory record Official record
Conditions
Melanoma
Interventions
rIL-21, Dacarbazine
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery

NCT03405155
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Nivolumab
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 19, 2026, 10:43 PM EDT